Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc, filed a statement of changes in beneficial ownership with the SEC on August 25, 2026, reporting the acquisition of deferred stock units dated August 21, 2026.
Key Highlights
- Reporting person: Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc (NYSE:ELAN)
- Transaction date: August 21, 2026, with the filing submitted on August 25, 2026
- Units acquired: 117.9362 deferred stock units (DSUs) acquired at a price of $23.97 per unit
- Post-transaction holdings: Simmons beneficially owned 25,130.1237 DSUs following the transaction, held directly
- Settlement terms: Each DSU represents the right to receive one share of Company common stock or the cash equivalent, settling after termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan
- Transaction code: A (acquisition), reported under Table II for derivative securities
Simmons DSU Acquisition Under Elanco Executive Deferral Plan
According to the filing, Jeffrey N. Simmons acquired 117.9362 deferred stock units in Elanco Animal Health Inc on August 21, 2026, under transaction code "A," indicating an acquisition. The stated price per unit was $23.97. Elanco Animal Health is a global animal health company whose shares trade on the New York Stock Exchange under the symbol ELAN. The filing was signed by Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons, on August 25, 2026.
The filing discloses that each deferred stock unit carries the right to receive one share of Company common stock or the cash equivalent. Settlement occurs following termination of employment or during a specified future year in accordance with the Executive Deferral and Stock Match Plan, as described in the filing's footnotes. Following the reported transaction, Simmons directly held a total of 25,130.1237 deferred stock units. No activity was reported in Table I covering non-derivative common stock holdings.
The transaction was reported as a direct ownership position. No amendment date was noted, indicating this was not a correction to a prior filing. The filing was submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934, which governs reporting obligations for officers and directors of public companies.
What Was Disclosed
The filing reported the acquisition of 117.9362 deferred stock units by Elanco Animal Health's President, CEO, and Director, Jeffrey N. Simmons, on August 21, 2026, at $23.97 per unit, bringing his total direct DSU holdings to 25,130.1237 units.



Please wait processing your request...